Uncategorized
Ocular Therapeutix™ Added to Nasdaq Biotechnology Index
BEDFORD, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank"gt;#OCUTXlt;/agt;--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has been selected for addition to the Nasdaq Biotechnology Index® (NASDAQ: NBI). Ocular Therapeutix’s addition to the NBI will become effective prior to market open on Monday, December 24, 2018. The Nasdaq Biotechnology Index is designed to trac